Están funcionando de forma IMPECABLE los puntos de recogida. Acérquese

New perspectives in #MultipleSclerosis care: Early use of high-efficacy DMTs shows promise in reducing relapses, slowing disease progression, and lowering MRI activity, especially in young or early-stage patients. By Celia Oreja-Guevara, Sergio Martínez-Yélamos & team journals.sagepub.com/doi/epdf/10.11…

Relapsing tumefactive demyelination lesions: An inflammatory brain pathology, not belonging to multiple sclerosis or myelin oligodendrocyte MOG/AQP4 associated disorders. Case report from Paola Perini Università di Padova ▶️ journals.sagepub.com/doi/full/10.11… 1/🧵

🔊 #SAVETHEDATE: Os informamos de la fecha y el programa de la III edición de nuestro curso "Neuro-inmunología:Más allá de la EM": 14 y 15 de Marzo de 2025 en el Hospital Clínic. Formato híbrido: presencial y online. Sigue leyendo para + info 👇

¡No faltes a la XVIII Jornada de Esclerosis Múltiple y sociedad! Tendrá lugar el 3️⃣1️⃣ de enero en el salón de actos del Hospital Universitario Ramón y Cajal a partir de las 09:00 h. Contará con dos mesas redondas protagonizadas por expertos. Asistencia libre hasta completar aforo

También se entregaron los premios a las mejores comunicaciones orales y pósters de la XXII Reunión Anual de la AMN. Enhorabuena a todos los premiados 👏😊 Dra Alicia González Martínez Juan Luis Chico Jaime Alonso

🗞️En el Dia Mundial de les Encefalitis recuperem 4 notícies destacades: Neuroimmunology Clinic Barcelona Hospital Clínic  1️⃣Investigadors del #CLÍNIC-#IDIBAPS identifiquen una nova encefalitis autoimmune 👉s.mtrbio.com/obidjdrbof

El Prof Dalmau explica el trabajo del grupo de patogénesis de las enfermedades neuronales autoinmunes Neuroimmunology Clinic Barcelona IDIBAPS

Is there a way to predict and treat neurological toxicities from immune checkpoint inhibitors used in oncology in a more targeted manner? Probably yes. If you are curious, here is the link to the open-access paper: frontiersin.org/journals/immun…

Non-ICANS neurological complications after CAR T-cell therapies: recommendations from EBMT Practice Harmonisation and Guidelines Committee. Great overview by Roser Velasco and colleagues thelancet.com/journals/lanon…

No added benefits in slowing MS disability progression were found in a study that increased Ocrevus dosing to 2-3 times the approved dose. bit.ly/4jnh67g #news

17 cutting-edge healthtech projects have been selected for the EIT Health Deep Tech Venture Builder programme! These are the innovators shaping tomorrow: loom.ly/hsT5S-c #DeepTech #HealthInnovation #HealthcareTransformation #VentureBuilding #HealthTech

Excited to kick off our journey with the Deep Tech Venture Builder (DTVB) programme! 📷 Thanks to EIT Health for supporting the transformation of academic research into real-world impact. Hopefully, together we can enable EMCare to make the invisible visible

New controversy available ⚖️ 📢Should disease-modifying therapy be discontinued in older patients with stable #MultipleSclerosis after long-term clinical and radiological stability? 1/🧵

Gadolinium enhancement lasted 14 months in a patient with aquaporin-4-positive myelitis #NMOSD, suggesting long-lasting enhancement could be crucial for diagnostic accuracy. Case report from Assistance Publique – Hôpitaux de Paris (AP-HP) Hôpital Pitié-Salpêtrière AP-HP ▶️ journals.sagepub.com/doi/abs/10.117… 1/🧵

📰 Check out pur latest publication in Nat Rev Neurology! Dr Caballero and colleagues gather the latest advances on #AutoimmuneNeuropathies, this pathophysiology and therapeutic arsenal. Don't miss! 👇🏿 nature.com/articles/s4158…

Neuroimmune interactions: How systemic immune activity can initiate/modulate CNS pathology, and how CNS-derived signals may shape peripheral immunity in #MultipleSclerosis. The Kenneth P Johnson Lecture ACTRIMS® from Adil Harroud The Neuro McGill University ▶️ journals.sagepub.com/doi/full/10.11…

New controversy available ⚖️ Anti-B-cell CAR-T therapy in #MultipleSclerosis is simply a more profound immunoablation? 1/🧵

🏅 El Dr. Josep Dalmau recibe el Premio Nacional de Investigación en Medicina y Ciencias de la Salud 2025 por su trayectoria y el descubrimiento de las encefalitis autoinmunes. Un orgullo para la neurología ✨🧠 clinicbarcelona.org/ca/noticies/jo…

Ya se conoce el ganador del Premio TecnoSEN a la mejor comunicación sobre nuevas tecnologías de la #RASEN25: reunion.sen.es/lxxvii/premios Enhorabuena Dr. Juan Luis Chico García!